Literature DB >> 25430696

The Expression of RAC1 and Mineralocorticoid Pathway-Dependent Genes are Associated With Different Responses to Salt Intake.

Alejandra Tapia-Castillo1, Cristian A Carvajal2, Carmen Campino2, Caroline Hill1, Fidel Allende3, Andrea Vecchiola2, Carmen Carrasco1, Rodrigo Bancalari4, Carolina Valdivia1, Carlos Lagos1, Alejandro Martinez-Aguayo4, Hernan Garcia4, Marlene Aglony4, Rene F Baudrand1, Alexis M Kalergis5, Luis F Michea6, Claudia A Riedel7, Carlos E Fardella8.   

Abstract

BACKGROUND: Rac1 upregulation has been implicated in salt-sensitive hypertension as a modulator of mineralocorticoid receptor (MR) activity. Rac1 could affect the expression of oxidative stress markers, such as hemoxigenase-1 (HO-1) or nuclear factor-B (NF-κB), and the expression of neutrophil gelatinase-associated lipocalin (NGAL), a cytokine upregulated upon MR activation. AIM: We evaluated RAC1 expression in relation of high salt intake and association with MR, NGAL, HO-1, and NF-κB expression, mineralo- and glucocorticoids levels, and inflammatory parameters. SUBJECTS AND METHODS: We studied 147 adult subjects. A food survey identified the dietary sodium (Na) intake. RAC1 expression was considered high or low according to the value found in normotensive subjects with low salt intake. We determined the gene expression of RAC1, MR, NGAL, HO-1, NF-κB, and 18S, isolated from peripheral leukocytes. We measured aldosterone, cortisol, sodium, potassium excretion, metalloproteinase (MMP9 y MMP2), and C-reactive protein.
RESULTS: We identified 126 subjects with high Na-intake, 18 subjects had high, and 108 low-RAC1 expression. The subjects with high-RAC1 expression showed a significant increase in MR (P = 0.0002), NGAL (P < 0.0001) HO-1 (P = 0.0004), and NF-κB (P < 0.0001) gene expression. We demonstrated an association between RAC1 expression and MR (R sp 0.64; P < 0.0001), NGAL (R sp 0.48; P < 0.0001), HO-1 (R sp 0.53; P < 0.0001), and NF-κB (R sp0.52; P < 0.0001). We did not identify any association between RAC1 and clinical or biochemical variables.
CONCLUSIONS: RAC1 expression was associated with an increase in MR, NGAL, NF-κB, and HO-1 expression, suggesting that RAC1 could be a mediator of cardiovascular damage induced by sodium, and may also useful to identify subjects with different responses to salt intake. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PBMC; RAC1; blood pressure; essential hypertension; gene expression; hypertension; salt intake.

Mesh:

Substances:

Year:  2014        PMID: 25430696     DOI: 10.1093/ajh/hpu224

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

Review 1.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

Authors:  Jennifer J DuPont; Iris Z Jaffe
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

Review 2.  What can urinary exosomes tell us?

Authors:  Rui Vitorino; Rita Ferreira; Sofia Guedes; Francisco Amado; Visith Thongboonkerd
Journal:  Cell Mol Life Sci       Date:  2021-01-28       Impact factor: 9.261

Review 3.  Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?

Authors:  Eric R Barros; Cristian A Carvajal
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-08       Impact factor: 5.555

Review 4.  Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.

Authors:  Stefania Gorini; Vincenzo Marzolla; Caterina Mammi; Andrea Armani; Massimiliano Caprio
Journal:  Biomolecules       Date:  2018-09-18

5.  Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess.

Authors:  Alejandra Tapia-Castillo; Dominic Guanzon; Carlos Palma; Andrew Lai; Eric Barros; Fidel Allende; Andrea Vecchiola; Carlos E Fardella; Carlos Salomón; Cristian A Carvajal
Journal:  J Transl Med       Date:  2019-11-27       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.